Primary Hyperparathyroidism and Skeletal Involvement: Bridging the Gap Between Guidelines and Real-World Practice
AACE Endocrinology and Diabetes · 2026-07
DOI: 10.1016/j.aed.2026.06.018 ↗Kurz gefasst
Leitlinie in der Zeitschrift AACE Endocrinology and Diabetes, 2026-07. Verfasst von Onnicha Amornariyakool und 3 weiteren Autor:innen. Die Arbeit nennt 141 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Chulabhorn Royal Academy.
Abstract (Originalsprache)
The clinical landscape of primary hyperparathyroidism (PHPT) has shifted over recent decades from a rare symptomatic disease characterized by "stones, bones, moans, and groans" to a predominantly asymptomatic biochemical diagnosis. Despite this transition, the skeleton remains the primary target organ, even in patients without overt clinical manifestations. Chronic elevation of parathyroid hormone (PTH) causes persistent high bone turnover and increases fracture risk. Skeletal involvement is therefore a major determinant of management, and parathyroidectomy (PTX) remains the only definitive curative therapy, with established benefits in reducing fracture risk. Contemporary international guidelines provide criteria for PTX; however, discrepancies persist between recommendations and real-world practice because of variations in guideline interpretation, patient characteristics, and healthcare system factors. Adjunctive tools for fracture risk assessment, including fracture risk assessment tool (FRAX) and trabecular bone score (TBS), have also gained increasing attention. The management of normocalcemic PHPT (NCPHPT), a distinct entity within the PHPT spectrum, is not formally addressed in current guidelines, although emerging evidence supports its association with skeletal involvement and potential benefit from PTX. This review synthesizes current recommendations and recent evidence and proposes a pragmatic framework for decision-making in PHPT with skeletal involvement.
Förderung
- Chulabhorn Royal Academy
Zitieren
APA
Amornariyakool, O., Dechates, B., Therawit, P., & Ngaosuwan, K. (2026). Primary Hyperparathyroidism and Skeletal Involvement: Bridging the Gap Between Guidelines and Real-World Practice. AACE Endocrinology and Diabetes. https://doi.org/10.1016/j.aed.2026.06.018
Vancouver
Amornariyakool O, Dechates B, Therawit P, Ngaosuwan K. Primary Hyperparathyroidism and Skeletal Involvement: Bridging the Gap Between Guidelines and Real-World Practice. AACE Endocrinology and Diabetes. 2026. doi:10.1016/j.aed.2026.06.018
BibTeX
@article{Amornariyakool2026,
author = {Amornariyakool, Onnicha and Dechates, Bothamai and Therawit, Phonthip and Ngaosuwan, Kanchana},
title = {Primary Hyperparathyroidism and Skeletal Involvement: Bridging the Gap Between Guidelines and Real-World Practice},
journal = {AACE Endocrinology and Diabetes},
year = {2026},
doi = {10.1016/j.aed.2026.06.018}
}
EUVIMED